Quantifying the Value of Personalized Medicines

Evidence from COX-2 Inhibitors

Published in: Forum for Health Economics and Policy, v. 16, no. 1, Apr. 2013, p. 1-22

Posted on RAND.org on January 01, 2013

by Neeraj Sood, Tomas Philipson, Peter J. Huckfeldt

Read More

Access further information on this document at Forum for Health Economics and Policy

This article was published outside of RAND. The full text of the article can be found at the link above.

We develop a conceptual framework for estimating the value of personalized medicines. We show that personalizing medicines generates value from two sources. The first is a market-expansion effect by persons who initiate treatment due to reduced pre-treatment uncertainty about the effectiveness or side effects of treatment. The second is a market-contraction effect due to discontinuation of treatment by persons unresponsive to treatment. We apply the conceptual framework to evaluate the value of a predictive test to assess whether patients are at elevated risk for cardiac complications from COX-2 inhibitors. We find that this predictive test would yield an overall value to patients of about $16 billion per year or $1284 per likely patient.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.